Evidence map›Paper›PMID 42429229›Full record

ReviewBioMed research international2026

Immunometabolic Reprogramming of Fibroblastic Reticular Cells in the Tumor Immune Microenvironment.

Tian Tian, Huimin Liu, Peiyan Liu, Shumin Ye, Yudi Wu, Jun Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tian TianDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0007-6411-556X
Huimin LiuDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0003-2439-9087
Peiyan LiuDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0004-2108-3711
Shumin YeDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0003-4188-3954
Yudi WuDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0006-4502-8500
Jun ZhouDepartment of Pulmonary and Critical Care Medicine, Changzhou Medical Center, Nanjing Medical University, Changzhou City, China, njmu.edu.cn.ORCID https://orcid.org/0009-0009-6920-8858

Funding

Changzhou Municipal Science and Technology Bureau CE20235057
6 · The paper itself

Abstract

Fibroblastic reticular cells (FRCs), as core stromal cells in secondary lymphoid tissues and the tumor immune microenvironment (TIME), undergo significant immunometabolic reprogramming, which regulates antitumor immune responses. This structured narrative review summarizes the immunometabolic reprogramming of FRCs across various cancers, emphasizing glucose metabolism, lipid remodeling, and amino acid metabolism in lung cancer, breast cancer, gastric cancer, lymphoma, head and neck tumors, and melanoma. Under hypoxia, nutrient stress, and inflammatory stimulation, FRCs enhance glycolysis, alter fatty acid synthesis/oxidation, and disrupt amino acid metabolism, leading to immunosuppressive metabolite secretion, cytokine profile changes, and the formation of immune niches. Understanding these cancer-specific molecular mechanisms can inform targeted immunometabolic therapies.

Indexed as

FibroblastsNeoplasmsTumor MicroenvironmentAnimalsHumansMetabolic Reprogrammingfibroblastic reticular cellimmunometabolic reprogrammingmultiple cancer typestumor immune microenvironment

Identifiers

PMID42429229
PMCPMC13352518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.